NT 10-Q - Priveterra Acquisition Corp. II (0001821606) (Filer)

8-K - Priveterra Acquisition Corp. II (0001821606) (Filer)

NT 10-K - Priveterra Acquisition Corp. II (0001821606) (Filer)

8-K - AEON Biopharma, Inc. (0001837607) (Filer)

S-1/A - AEON Biopharma, Inc. (0001837607) (Filer)

10-Q - AEON Biopharma, Inc. (0001837607) (Filer)

8-K - AEON Biopharma, Inc. (0001837607) (Filer)

S-1/A - AEON Biopharma, Inc. (0001837607) (Filer)

8-K - AEON Biopharma, Inc. (0001837607) (Filer)

8-K - AEON Biopharma, Inc. (0001837607) (Filer)

Priveterra Acquisition Corp. II (NASDAQ:PMGMU, PMGM, PMGMW))) (the "Company") today announced that on April 29, 2024, the Company received a notice (the "10-K Notice") from the staff of the Nasdaq Listing Qualifications department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that, because the Company had not yet filed its Annual Report on Form 10-K for the period ended December 31, 2023 (the "Form 10-K"), the Company is not in compliance with Nasdaq Listing Rules for continued listing and, accordingly, such delinquency may serve as a separate basis for the delisting of the Company's securities from Nasdaq. The 10-K Notice also states that the Nasdaq Hearings Panel (the "P

Common stock and warrants of combined company will be listed on the New York Stock Exchange American under the symbols AEON and AEON WS, respectively Phase 2 topline data with ABP-450 for the preventive treatment of episodic migraine is anticipated to readout this fall $50 million financing provides sufficient cash runway to fund operations beyond the anticipated Phase 2 data announcement this fall IRVINE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON, AEON WS))), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, annou

Priveterra Acquisition Corp. (NASDAQ:PMGM) ("Priveterra"), a special purpose acquisition company led by Chairman & CEO, Robert Palmisano, along with President, Vikram Malik, and COO and CFO, Oleg Grodnensky, today announced the successful completion of its business combination (the "Business Combination") with AEON Biopharma, Inc. ("AEON"), a Phase 3 stage-ready biopharmaceutical company developing a proprietary neurotoxin with initial focus on preventive treatments for episodic and chronic migraines along with other debilitating medical conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230721427813/en/ The resulting co

Priveterra Acquisition Corp. (NASDAQ:PMGM) ("Priveterra" and, after the consummation of its pending business combination (the "Business Combination") and following its name change to AEON Biopharma, Inc., "New AEON") today announced that NYSE Regulation, on July 13, 2023, authorized New AEON common stock ("New AEON Common Stock") and New AEON warrants to be listed on NYSE American LLC ("NYSE") upon the Business Combination with AEON Biopharma, Inc., ("AEON") following which AEON will be a wholly owned subsidiary of Priveterra and Priveterra will change its name to AEON Biopharma, Inc. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home

Priveterra Acquisition Corp. (NASDAQ:PMGM) ("Priveterra" and, after the consummation of its pending business combination (the "Business Combination") and following its name change to AEON Biopharma, Inc., "New AEON") today announced that, upon the Business Combination with AEON Biopharma, Inc, ("AEON") following which AEON will be a wholly owned subsidiary of Priveterra and Priveterra will change its name to AEON Biopharma, Inc., New AEON Common Stock will be listed on NYSE American LLC ("NYSE"). The decision to list on NYSE was made in connection with the Business Combination and enables the combined company to be listed alongside other innovative companies that are also listed on NYSE. T

IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, and Priveterra Acquisition Corp. (NASDAQ:PMGM) ("Priveterra"), a special purpose acquisition company, today announced that a total of up to $125 million in funding has been arranged in connection with the proposed business combination between AEON and Priveterra. The funding includes approximately $50 million of committed financing from existing (including $20 million of previously announced financing) and new AEON investors as

IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, and Priveterra Acquisition Corp. (NASDAQ:PMGM) ("Priveterra"), a special purpose acquisition company, today announced that at least $20 million in additional funding has been committed by existing AEON investors. The commitments have been delivered in connection with the proposed business combination between AEON and Priveterra announced on December 13, 2022, and represent nearly half of the minimum cash requirement for the pro

AEON Biopharma, Inc. ("AEON" or the "Company"), a clinical-stage biopharmaceutical company developing a proprietary botulinum toxin for the treatment of multiple debilitating medical conditions, and Priveterra Acquisition Corp., ((PMGM) (Priveterra), a special purpose acquisition company, today announced the filing of Form S-4 Registration Statement ("S-4") with the U.S. Securities and Exchange Commission ("SEC") regarding the recently announced business combination between the two companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221226005060/en/ To learn more about AEON and the development of its uniquely positioned the

– Topline data expected to be announced in 2H 2023 – – Topline data from the Company's Phase 2 trial in preventive treatment of chronic migraine expected to be announced in 1H 2024 – IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company"), a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) for therapeutic indications, and Priveterra Acquisition Corp. (NASDAQ:PMGM) ("Priveterra"), a special purpose acquisition company (SPAC), today announced the completion of patient enrollment in the Phase 2 study of ABP-450 for the preventive treatment of ep

– Positive topline data from Phase 2 study of ABP-450 for cervical dystonia announced in September 2022 – – Topline data from Phase 2 study of ABP-450 for episodic migraine expected in Q4 2023 – –Robert Palmisano of Priveterra to become chairman of the Board of Directors; combined company to be led by AEON CEO Marc Forth – – Transaction values the combined company at a post-money equity value of $475.5M and is expected to provide $276M in gross cash proceeds – – Merger anticipated to close in 1H 2023 – IRVINE, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company"), a private clinical-stage biopharmaceutical company focused on the developmen

4 - AEON Biopharma, Inc. (0001837607) (Issuer)

4 - AEON Biopharma, Inc. (0001837607) (Issuer)

4 - AEON Biopharma, Inc. (0001837607) (Issuer)

4 - AEON Biopharma, Inc. (0001837607) (Issuer)

4 - AEON Biopharma, Inc. (0001837607) (Issuer)

3 - AEON Biopharma, Inc. (0001837607) (Issuer)

3 - AEON Biopharma, Inc. (0001837607) (Issuer)

4 - AEON Biopharma, Inc. (0001837607) (Issuer)

4 - AEON Biopharma, Inc. (0001837607) (Issuer)

4 - AEON Biopharma, Inc. (0001837607) (Issuer)

- SEC Filing

Priveterra Acquisition Corp (NASDAQ:PMGM) on Monday announced the closing of its business combination with AEON Biopharma. What To Know: Special purpose acquisition company Priveterra has merged with AEON Biopharma. Priveterra changed its name to AEON Biopharma and has commenced trading on the New York Stock Exchange under the ticker "AEON." In addition, AEON announced the closing of funding arrangements of up to $125 million, which includes $50 million of committed financing from existing and new AEON investors, as well as cash from Priveterra's trust account following redemptions. "The capital we have raised through these recent transactions will help fund our clinical development of AB

Priveterra Acquisition Corp. (NASDAQ:PMGM) ("Priveterra"), a special purpose acquisition company led by Chairman & CEO, Robert Palmisano, along with President, Vikram Malik, and COO and CFO, Oleg Grodnensky, today announced the successful completion of its business combination (the "Business Combination") with AEON Biopharma, Inc. ("AEON"), a Phase 3 stage-ready biopharmaceutical company developing a proprietary neurotoxin with initial focus on preventive treatments for episodic and chronic migraines along with other debilitating medical conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230721427813/en/ The resulting co

Gainers Digital World Acquisition Corp. (NASDAQ:DWAC) jumped 69% to $22.59 after the company announced it reached a settlement with the SEC. Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) gained 33% to $8.63. Evelo Biosciences, Inc. (NASDAQ:EVLO) shares jumped 30.8% to $12.90 after the company terminated sublease agreement with Bio-Rad Laboratories. Phunware, Inc. (NASDAQ:PHUN) rose 20.5% to $0.4670. Phunware recently announced strategic cost saving measures to accelerate path to profitability. Guardforce AI Co., Limited (NASDAQ:GFAI) gained 20% to $7.73. Guardforce AI shares jumped 57% on Thursday after the company announced it partnered with Concorde Security to launch a new robotic se

U.S. stocks traded higher this morning, with the Dow Jones gaining around 50 points on Friday. Following the market opening Friday, the Dow traded up 0.14% to 35,275.55 while the NASDAQ rose 0.52% to 14,135.92. The S&P 500, also rose, gaining, 0.32% to 4,549.47. Check This Out: Galectin Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying  Leading and Lagging Sectors Information technology shares climbed by 0.7% on Friday. In trading on Friday, materials shares fell by 0.3%.  Top Headline American Express Company (NYSE:AXP) reported better-than-expected earnings for its second quarter and reaffirmed its FY23 outlook. American Express posted quarterly earnings of $2.89 per

AEON will be a wholly owned subsidiary of Priveterra and Priveterra will change its name to AEON Biopharma, Inc. Trading is expected to begin on NYSE on July 24, 2023, under the new ticker symbol "AEON" for the New AEON Common Stock following the consummation of the Business Combination, which is expected to occur on July 21, 2023

Gainers TRxADE HEALTH, Inc. (NASDAQ:MEDS) shares surged 84.1% to $15.54 in pre-market trading after jumping over 15% on Friday. Superlatus, Inc. signed a binding letter of intent to be acquired by TRxADE HEALTH. Digital Media Solutions, Inc. (NYSE:DMS) shares gained 71.4% to $0.5750 in pre-market trading after gaining around 5% on Friday. Digital Media Solutions recently reported slightly worse-than-expected Q1 sales results. INVO Bioscience, Inc. (NASDAQ:INVO) shares rose 70.8% to $0.2819 in pre-market trading after dropping 5% on Friday. SQZ Biotechnologies Company (NYSE:SQZ) shares rose 40% to $0.56 in pre-market trading after dropping around 23% on Friday. Eco Wave Power Global AB

https://www.aeonbiopharma.com/2023/01/aeon-biopharma-and-priveterra-acquisition-corp-announce-filing-of-s-4-registration-statement-for-proposed-business-combination-2/

AEON Biopharma, Inc. ("AEON" or the "Company"), a clinical-stage biopharmaceutical company developing a proprietary botulinum toxin for the treatment of multiple debilitating medical conditions, and Priveterra Acquisition Corp., ((PMGM) (Priveterra), a special purpose acquisition company, today announced the filing of Form S-4 Registration Statement ("S-4") with the U.S. Securities and Exchange Commission ("SEC") regarding the recently announced business combination between the two companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221226005060/en/ To learn more about AEON and the development of its uniquely positioned th

SC 13G - AEON Biopharma, Inc. (0001837607) (Subject)

SC 13G/A - AEON Biopharma, Inc. (0001837607) (Subject)

SC 13D/A - AEON Biopharma, Inc. (0001837607) (Subject)

SC 13D - AEON Biopharma, Inc. (0001837607) (Subject)

SC 13G - AEON Biopharma, Inc. (0001837607) (Subject)

SC 13D - AEON Biopharma, Inc. (0001837607) (Subject)

SC 13G/A - Priveterra Acquisition Corp. (0001837607) (Subject)

SC 13G/A - Priveterra Acquisition Corp. (0001837607) (Subject)

SC 13G - Priveterra Acquisition Corp. (0001837607) (Subject)